Risk of incident active tuberculosis disease in patients treated with non-steroidal anti-inflammatory drugs: a population-based study

Mycobacterium tuberculosis (TB) is one of the world's most devastating public health threats. Our goal is to evaluate whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) affect the risk of new incident active TB disease. We conducted a nested case-control analysis by using a 1 mil...

Full description

Saved in:
Bibliographic Details
Published inBMC pulmonary medicine Vol. 17; no. 1; pp. 82 - 8
Main Authors Wu, Chun-Wei, Wu, Jiunn-Yih, Lee, Meng-Tse Gabriel, Lai, Chih-Cheng, Wu, I-Lin, Tsai, Yi-Wen, Chang, Shy-Shin, Lee, Chien-Chang
Format Journal Article
LanguageEnglish
Published England BioMed Central 04.05.2017
BMC
Subjects
Online AccessGet full text
ISSN1471-2466
1471-2466
DOI10.1186/s12890-017-0425-3

Cover

Loading…
Abstract Mycobacterium tuberculosis (TB) is one of the world's most devastating public health threats. Our goal is to evaluate whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) affect the risk of new incident active TB disease. We conducted a nested case-control analysis by using a 1 million longitudinally followed cohort, from Taiwan's national health insurance research database. Effects of NSAIDs on active TB were estimated by conditional logistic regression and adjusted using a TB-specific disease risk score (DRS). NSAIDs exposures were defined as having a prescription record of NSAIDs ≧ 7 days that ended between 31 and 90 days prior to the index date. A total of 123,419 users of traditional NSAIDs, 16,392 users of cyclooxygenase-2 selective inhibitor (Coxibs), and 4706 incident cases of active TB were identified. Compared with nonusers, use of traditional NSAIDs was associated with an increased risk of TB in the unadjusted analysis ([RR], 1.39; 95% [CI], 1.24 - 1.57 and DRS adjusted analysis ([ARR], 1.30; 95% [CI], 1.15- 1.47). However, use of Coxibs was not associated with a significant increase in the risk of TB after DRS adjustment ([ARR], 1.23; 95% [CI], 0.89 - 1.70). In this large population-based study, we found that subjects using traditional NSAIDs were associated with increased risk for active TB. We did not find evidence for a causative mechanism between traditional NSAIDs and TB, and more research is required to verify whether the association between traditional NSAIDs and TB is causal, or simply reflects an increased use of anti-inflammatory drugs in the early phases of TB onset.
AbstractList Abstract Background Mycobacterium tuberculosis (TB) is one of the world’s most devastating public health threats. Our goal is to evaluate whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) affect the risk of new incident active TB disease. Methods We conducted a nested case-control analysis by using a 1 million longitudinally followed cohort, from Taiwan’s national health insurance research database. Effects of NSAIDs on active TB were estimated by conditional logistic regression and adjusted using a TB-specific disease risk score (DRS). NSAIDs exposures were defined as having a prescription record of NSAIDs ≧ 7 days that ended between 31 and 90 days prior to the index date. Results A total of 123,419 users of traditional NSAIDs, 16,392 users of cyclooxygenase-2 selective inhibitor (Coxibs), and 4706 incident cases of active TB were identified. Compared with nonusers, use of traditional NSAIDs was associated with an increased risk of TB in the unadjusted analysis ([RR], 1.39; 95% [CI], 1.24 – 1.57 and DRS adjusted analysis ([ARR], 1.30; 95% [CI], 1.15– 1.47). However, use of Coxibs was not associated with a significant increase in the risk of TB after DRS adjustment ([ARR], 1.23; 95% [CI], 0.89 – 1.70). Conclusions In this large population-based study, we found that subjects using traditional NSAIDs were associated with increased risk for active TB. We did not find evidence for a causative mechanism between traditional NSAIDs and TB, and more research is required to verify whether the association between traditional NSAIDs and TB is causal, or simply reflects an increased use of anti-inflammatory drugs in the early phases of TB onset.
Background Mycobacterium tuberculosis (TB) is one of the world’s most devastating public health threats. Our goal is to evaluate whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) affect the risk of new incident active TB disease. Methods We conducted a nested case-control analysis by using a 1 million longitudinally followed cohort, from Taiwan’s national health insurance research database. Effects of NSAIDs on active TB were estimated by conditional logistic regression and adjusted using a TB-specific disease risk score (DRS). NSAIDs exposures were defined as having a prescription record of NSAIDs ≧ 7 days that ended between 31 and 90 days prior to the index date. Results A total of 123,419 users of traditional NSAIDs, 16,392 users of cyclooxygenase-2 selective inhibitor (Coxibs), and 4706 incident cases of active TB were identified. Compared with nonusers, use of traditional NSAIDs was associated with an increased risk of TB in the unadjusted analysis ([RR], 1.39; 95% [CI], 1.24 - 1.57 and DRS adjusted analysis ([ARR], 1.30; 95% [CI], 1.15- 1.47). However, use of Coxibs was not associated with a significant increase in the risk of TB after DRS adjustment ([ARR], 1.23; 95% [CI], 0.89 - 1.70). Conclusions In this large population-based study, we found that subjects using traditional NSAIDs were associated with increased risk for active TB. We did not find evidence for a causative mechanism between traditional NSAIDs and TB, and more research is required to verify whether the association between traditional NSAIDs and TB is causal, or simply reflects an increased use of anti-inflammatory drugs in the early phases of TB onset.
Mycobacterium tuberculosis (TB) is one of the world's most devastating public health threats. Our goal is to evaluate whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) affect the risk of new incident active TB disease.BACKGROUNDMycobacterium tuberculosis (TB) is one of the world's most devastating public health threats. Our goal is to evaluate whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) affect the risk of new incident active TB disease.We conducted a nested case-control analysis by using a 1 million longitudinally followed cohort, from Taiwan's national health insurance research database. Effects of NSAIDs on active TB were estimated by conditional logistic regression and adjusted using a TB-specific disease risk score (DRS). NSAIDs exposures were defined as having a prescription record of NSAIDs ≧ 7 days that ended between 31 and 90 days prior to the index date.METHODSWe conducted a nested case-control analysis by using a 1 million longitudinally followed cohort, from Taiwan's national health insurance research database. Effects of NSAIDs on active TB were estimated by conditional logistic regression and adjusted using a TB-specific disease risk score (DRS). NSAIDs exposures were defined as having a prescription record of NSAIDs ≧ 7 days that ended between 31 and 90 days prior to the index date.A total of 123,419 users of traditional NSAIDs, 16,392 users of cyclooxygenase-2 selective inhibitor (Coxibs), and 4706 incident cases of active TB were identified. Compared with nonusers, use of traditional NSAIDs was associated with an increased risk of TB in the unadjusted analysis ([RR], 1.39; 95% [CI], 1.24 - 1.57 and DRS adjusted analysis ([ARR], 1.30; 95% [CI], 1.15- 1.47). However, use of Coxibs was not associated with a significant increase in the risk of TB after DRS adjustment ([ARR], 1.23; 95% [CI], 0.89 - 1.70).RESULTSA total of 123,419 users of traditional NSAIDs, 16,392 users of cyclooxygenase-2 selective inhibitor (Coxibs), and 4706 incident cases of active TB were identified. Compared with nonusers, use of traditional NSAIDs was associated with an increased risk of TB in the unadjusted analysis ([RR], 1.39; 95% [CI], 1.24 - 1.57 and DRS adjusted analysis ([ARR], 1.30; 95% [CI], 1.15- 1.47). However, use of Coxibs was not associated with a significant increase in the risk of TB after DRS adjustment ([ARR], 1.23; 95% [CI], 0.89 - 1.70).In this large population-based study, we found that subjects using traditional NSAIDs were associated with increased risk for active TB. We did not find evidence for a causative mechanism between traditional NSAIDs and TB, and more research is required to verify whether the association between traditional NSAIDs and TB is causal, or simply reflects an increased use of anti-inflammatory drugs in the early phases of TB onset.CONCLUSIONSIn this large population-based study, we found that subjects using traditional NSAIDs were associated with increased risk for active TB. We did not find evidence for a causative mechanism between traditional NSAIDs and TB, and more research is required to verify whether the association between traditional NSAIDs and TB is causal, or simply reflects an increased use of anti-inflammatory drugs in the early phases of TB onset.
Mycobacterium tuberculosis (TB) is one of the world's most devastating public health threats. Our goal is to evaluate whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) affect the risk of new incident active TB disease. We conducted a nested case-control analysis by using a 1 million longitudinally followed cohort, from Taiwan's national health insurance research database. Effects of NSAIDs on active TB were estimated by conditional logistic regression and adjusted using a TB-specific disease risk score (DRS). NSAIDs exposures were defined as having a prescription record of NSAIDs ≧ 7 days that ended between 31 and 90 days prior to the index date. A total of 123,419 users of traditional NSAIDs, 16,392 users of cyclooxygenase-2 selective inhibitor (Coxibs), and 4706 incident cases of active TB were identified. Compared with nonusers, use of traditional NSAIDs was associated with an increased risk of TB in the unadjusted analysis ([RR], 1.39; 95% [CI], 1.24 - 1.57 and DRS adjusted analysis ([ARR], 1.30; 95% [CI], 1.15- 1.47). However, use of Coxibs was not associated with a significant increase in the risk of TB after DRS adjustment ([ARR], 1.23; 95% [CI], 0.89 - 1.70). In this large population-based study, we found that subjects using traditional NSAIDs were associated with increased risk for active TB. We did not find evidence for a causative mechanism between traditional NSAIDs and TB, and more research is required to verify whether the association between traditional NSAIDs and TB is causal, or simply reflects an increased use of anti-inflammatory drugs in the early phases of TB onset.
ArticleNumber 82
Author Lee, Meng-Tse Gabriel
Wu, Jiunn-Yih
Lai, Chih-Cheng
Wu, I-Lin
Chang, Shy-Shin
Wu, Chun-Wei
Tsai, Yi-Wen
Lee, Chien-Chang
Author_xml – sequence: 1
  givenname: Chun-Wei
  surname: Wu
  fullname: Wu, Chun-Wei
– sequence: 2
  givenname: Jiunn-Yih
  surname: Wu
  fullname: Wu, Jiunn-Yih
– sequence: 3
  givenname: Meng-Tse Gabriel
  surname: Lee
  fullname: Lee, Meng-Tse Gabriel
– sequence: 4
  givenname: Chih-Cheng
  surname: Lai
  fullname: Lai, Chih-Cheng
– sequence: 5
  givenname: I-Lin
  surname: Wu
  fullname: Wu, I-Lin
– sequence: 6
  givenname: Yi-Wen
  surname: Tsai
  fullname: Tsai, Yi-Wen
– sequence: 7
  givenname: Shy-Shin
  surname: Chang
  fullname: Chang, Shy-Shin
– sequence: 8
  givenname: Chien-Chang
  surname: Lee
  fullname: Lee, Chien-Chang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28472944$$D View this record in MEDLINE/PubMed
BookMark eNp1kttqFTEUhoNU7EEfwBsJeOPNaDKTycELoRSrhYIgeh1WDrOb7cxkm2Qq-wF872Z3t9IWvEpIvvXxs9Y6RgdznD1Cryl5T6nkHzJtpSINoaIhrO2b7hk6okzQpmWcHzy4H6LjnNekgrLvXqDDVjLRKsaO0N_vIf_CccBhtsH5uWCwJVx7XBbjk13GmEPGLmQP2VcIb6CEimVckofiHf4TyhWuwZpcfIrBwYhhLqEJ8zDCNEGJaYtdWlb5Iwa8iZtlrIrKm2p0OJfFbV-i5wOM2b-6O0_Qz_PPP86-NpffvlycnV42lqmuNKIHxUAypzj0YoCW-G4Q1pOWKUb8AKZvqXFK1ufWOq4kUEG4UtR52ZGhO0EXe6-LsNabFCZIWx0h6NuHmFYaUgl29No4QnpJB8KNYQaEsYOkveE9AdYJ3lbXp71rs5jJO1ubkmB8JH38M4crvYrXumd1dkpUwbs7QYq_F5-LnkK2fhxh9nHJmkrFCSOcyYq-fYKu45Lm2ipNFemJYELtqDcPE_2Lcj_tCog9YFPMOflB21Buh1EDhlFTond7pfd7peu66N1e6a5W0ieV9_L_19wAnarSeQ
CitedBy_id crossref_primary_10_1038_s41385_019_0226_5
crossref_primary_10_1016_j_tube_2022_102244
crossref_primary_10_1183_16000617_0127_2022
crossref_primary_10_1371_journal_pone_0205807
crossref_primary_10_3389_fmicb_2018_02603
crossref_primary_10_3389_fimmu_2021_623941
crossref_primary_10_1038_s42003_019_0530_3
crossref_primary_10_14336_AD_2023_0311
crossref_primary_10_1080_14740338_2019_1612872
Cites_doi 10.1111/j.1476-5381.1973.tb08270.x
10.1093/aje/kwg231
10.2165/11534590-000000000-00000
10.1002/hep.25509
10.1111/j.1365-4632.2011.05310.x
10.1164/rccm.200904-0549OC
10.1002/pds.2140
10.1016/j.jaad.2012.12.966
10.1093/cid/cir939
10.1038/newbio238104a0
10.1016/0002-9343(80)90363-0
10.1016/j.jclinepi.2010.10.004
10.1002/pds.3231
10.1002/pds.755
10.2307/2530744
10.1016/S0929-6646(08)60076-5
10.1056/NEJM200011233432103
10.1016/S0140-6736(10)62173-3
10.1377/hlthaff.22.3.77
10.1111/bcp.12239
10.1001/jama.284.10.1247
10.1002/art.24476
ContentType Journal Article
Copyright Copyright BioMed Central 2017
The Author(s). 2017
Copyright_xml – notice: Copyright BioMed Central 2017
– notice: The Author(s). 2017
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12890-017-0425-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1471-2466
EndPage 8
ExternalDocumentID oai_doaj_org_article_bd00581f06bb4ba7bcf815b650a43762
PMC5418697
28472944
10_1186_s12890_017_0425_3
Genre Journal Article
Comparative Study
GeographicLocations Taiwan
GeographicLocations_xml – name: Taiwan
GrantInformation_xml – fundername: ;
  grantid: MOST 104-2314-B-002 -039 -MY3, and MOST 105-2811-B-002-031
GroupedDBID ---
0R~
23N
2WC
53G
5GY
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
EMB
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
7TO
7XB
8FK
AHSBF
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c493t-75a94a84d96a57fa20e3f7ce024940efab521bd98e3f2cd698a1706991de830f3
IEDL.DBID M48
ISSN 1471-2466
IngestDate Wed Aug 27 01:29:53 EDT 2025
Thu Aug 21 14:13:22 EDT 2025
Thu Jul 10 23:49:23 EDT 2025
Fri Jul 25 03:28:29 EDT 2025
Thu Jan 02 23:11:09 EST 2025
Thu Apr 24 23:02:27 EDT 2025
Tue Jul 01 02:40:14 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords NSAIDs
Tuberculosis
Coxibs
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c493t-75a94a84d96a57fa20e3f7ce024940efab521bd98e3f2cd698a1706991de830f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
OpenAccessLink https://doaj.org/article/bd00581f06bb4ba7bcf815b650a43762
PMID 28472944
PQID 1905074798
PQPubID 44785
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_bd00581f06bb4ba7bcf815b650a43762
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5418697
proquest_miscellaneous_1896040648
proquest_journals_1905074798
pubmed_primary_28472944
crossref_citationtrail_10_1186_s12890_017_0425_3
crossref_primary_10_1186_s12890_017_0425_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-05-04
PublicationDateYYYYMMDD 2017-05-04
PublicationDate_xml – month: 05
  year: 2017
  text: 2017-05-04
  day: 04
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC pulmonary medicine
PublicationTitleAlternate BMC Pulm Med
PublicationYear 2017
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References SD Lawn (425_CR1) 2011; 378
R Paulose-Ram (425_CR3) 2003; 12
JH Lubin (425_CR22) 1984; 40
R Flower (425_CR6) 1972; 238
HH Lin (425_CR20) 2009; 180
H Tomasson (425_CR13) 1984; 130
JJ Gagne (425_CR21) 2011; 64
P Brassard (425_CR14) 2009; 61
M Duong (425_CR5) 2014; 77
JR Vane (425_CR8) 1971; 231
RI Horwitz (425_CR24) 1980; 68
C Bombardier (425_CR9) 2000; 343
WA Ray (425_CR18) 2003; 158
RJ Glynn (425_CR23) 2012; 21
MA Baker (425_CR19) 2012; 54
SH Ferreira (425_CR7) 1973; 49
CH Chang (425_CR11) 2011; 20
CH Chang (425_CR17) 2012; 55
MS Lee (425_CR16) 2012; 51
Y-C Wu (425_CR25) 2007; 106
MM Tielemans (425_CR4) 2010; 33
J-FR Lu (425_CR15) 2003; 22
425_CR2
YJ Chen (425_CR12) 2013; 69
FE Silverstein (425_CR10) 2000; 284
21420161 - Lancet. 2011 Jul 2;378(9785):57-72
21618340 - Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):763-71
5284360 - Nat New Biol. 1971 Jun 23;231(25):232-5
6692212 - Can Med Assoc J. 1984 Feb 1;130(3):275-8
19248128 - Arthritis Rheum. 2009 Mar 15;61(3):300-4
23171012 - Int J Dermatol. 2012 Dec;51(12):1454-60
7355896 - Am J Med. 1980 Feb;68(2):255-8
14585769 - Am J Epidemiol. 2003 Nov 1;158(9):915-20
4505422 - Nat New Biol. 1972 Jul 26;238(82):104-6
24102791 - Br J Clin Pharmacol. 2014 May;77(5):887-95
22238171 - Clin Infect Dis. 2012 Mar;54(6):818-25
4207046 - Br J Pharmacol. 1973 Sep;49(1):86-97
18194906 - J Formos Med Assoc. 2007 Dec;106(12):1007-12
12812012 - Pharmacoepidemiol Drug Saf. 2003 Jun;12(4):315-26
22135104 - Hepatology. 2012 May;55(5):1462-72
10979111 - JAMA. 2000 Sep 13;284(10):1247-55
22552989 - Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:138-47
12757274 - Health Aff (Millwood). 2003 May-Jun;22(3):77-88
6375751 - Biometrics. 1984 Mar;40(1):63-75
20486727 - Drug Saf. 2010 Jun 1;33(6):443-53
11087881 - N Engl J Med. 2000 Nov 23;343 (21):1520-8, 2 p following 1528
19542475 - Am J Respir Crit Care Med. 2009 Sep 1;180(5):475-80
23375515 - J Am Acad Dermatol. 2013 Jul;69(1):25-33
21208778 - J Clin Epidemiol. 2011 Jul;64(7):749-59
References_xml – volume: 49
  start-page: 86
  issue: 1
  year: 1973
  ident: 425_CR7
  publication-title: Br J Pharmacol
  doi: 10.1111/j.1476-5381.1973.tb08270.x
– volume: 158
  start-page: 915
  issue: 9
  year: 2003
  ident: 425_CR18
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwg231
– volume: 33
  start-page: 443
  issue: 6
  year: 2010
  ident: 425_CR4
  publication-title: Drug Saf
  doi: 10.2165/11534590-000000000-00000
– volume: 55
  start-page: 1462
  issue: 5
  year: 2012
  ident: 425_CR17
  publication-title: Hepatology
  doi: 10.1002/hep.25509
– volume: 130
  start-page: 275
  issue: 3
  year: 1984
  ident: 425_CR13
  publication-title: Can Med Assoc J
– volume: 51
  start-page: 1454
  issue: 12
  year: 2012
  ident: 425_CR16
  publication-title: Int J Dermatol
  doi: 10.1111/j.1365-4632.2011.05310.x
– volume: 180
  start-page: 475
  issue: 5
  year: 2009
  ident: 425_CR20
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200904-0549OC
– volume: 20
  start-page: 763
  issue: 7
  year: 2011
  ident: 425_CR11
  publication-title: Pharmacoepidemiol Drug Saf
  doi: 10.1002/pds.2140
– ident: 425_CR2
– volume: 69
  start-page: 25
  issue: 1
  year: 2013
  ident: 425_CR12
  publication-title: J Am Acad Dermatol
  doi: 10.1016/j.jaad.2012.12.966
– volume: 54
  start-page: 818
  issue: 6
  year: 2012
  ident: 425_CR19
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cir939
– volume: 238
  start-page: 104
  issue: 82
  year: 1972
  ident: 425_CR6
  publication-title: Nat New Biol
  doi: 10.1038/newbio238104a0
– volume: 68
  start-page: 255
  issue: 2
  year: 1980
  ident: 425_CR24
  publication-title: Am J Med
  doi: 10.1016/0002-9343(80)90363-0
– volume: 231
  start-page: 232
  issue: 25
  year: 1971
  ident: 425_CR8
  publication-title: Nature
– volume: 64
  start-page: 749
  issue: 7
  year: 2011
  ident: 425_CR21
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2010.10.004
– volume: 21
  start-page: 138
  issue: Suppl 2
  year: 2012
  ident: 425_CR23
  publication-title: Pharmacoepidemiol Drug Saf
  doi: 10.1002/pds.3231
– volume: 12
  start-page: 315
  issue: 4
  year: 2003
  ident: 425_CR3
  publication-title: Pharmacoepidemiol Drug Saf
  doi: 10.1002/pds.755
– volume: 40
  start-page: 63
  issue: 1
  year: 1984
  ident: 425_CR22
  publication-title: Biometrics
  doi: 10.2307/2530744
– volume: 106
  start-page: 1007
  issue: 12
  year: 2007
  ident: 425_CR25
  publication-title: J Formos Med Assoc
  doi: 10.1016/S0929-6646(08)60076-5
– volume: 343
  start-page: 1520
  issue: 21
  year: 2000
  ident: 425_CR9
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200011233432103
– volume: 378
  start-page: 57
  issue: 9785
  year: 2011
  ident: 425_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)62173-3
– volume: 22
  start-page: 77
  issue: 3
  year: 2003
  ident: 425_CR15
  publication-title: Health Affairs
  doi: 10.1377/hlthaff.22.3.77
– volume: 77
  start-page: 887
  issue: 5
  year: 2014
  ident: 425_CR5
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.12239
– volume: 284
  start-page: 1247
  issue: 10
  year: 2000
  ident: 425_CR10
  publication-title: JAMA
  doi: 10.1001/jama.284.10.1247
– volume: 61
  start-page: 300
  issue: 3
  year: 2009
  ident: 425_CR14
  publication-title: Arthritis Rheum
  doi: 10.1002/art.24476
– reference: 7355896 - Am J Med. 1980 Feb;68(2):255-8
– reference: 4505422 - Nat New Biol. 1972 Jul 26;238(82):104-6
– reference: 4207046 - Br J Pharmacol. 1973 Sep;49(1):86-97
– reference: 6692212 - Can Med Assoc J. 1984 Feb 1;130(3):275-8
– reference: 10979111 - JAMA. 2000 Sep 13;284(10):1247-55
– reference: 21420161 - Lancet. 2011 Jul 2;378(9785):57-72
– reference: 24102791 - Br J Clin Pharmacol. 2014 May;77(5):887-95
– reference: 19542475 - Am J Respir Crit Care Med. 2009 Sep 1;180(5):475-80
– reference: 6375751 - Biometrics. 1984 Mar;40(1):63-75
– reference: 19248128 - Arthritis Rheum. 2009 Mar 15;61(3):300-4
– reference: 22238171 - Clin Infect Dis. 2012 Mar;54(6):818-25
– reference: 23375515 - J Am Acad Dermatol. 2013 Jul;69(1):25-33
– reference: 18194906 - J Formos Med Assoc. 2007 Dec;106(12):1007-12
– reference: 21618340 - Pharmacoepidemiol Drug Saf. 2011 Jul;20(7):763-71
– reference: 12757274 - Health Aff (Millwood). 2003 May-Jun;22(3):77-88
– reference: 22552989 - Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:138-47
– reference: 12812012 - Pharmacoepidemiol Drug Saf. 2003 Jun;12(4):315-26
– reference: 14585769 - Am J Epidemiol. 2003 Nov 1;158(9):915-20
– reference: 22135104 - Hepatology. 2012 May;55(5):1462-72
– reference: 5284360 - Nat New Biol. 1971 Jun 23;231(25):232-5
– reference: 20486727 - Drug Saf. 2010 Jun 1;33(6):443-53
– reference: 21208778 - J Clin Epidemiol. 2011 Jul;64(7):749-59
– reference: 23171012 - Int J Dermatol. 2012 Dec;51(12):1454-60
– reference: 11087881 - N Engl J Med. 2000 Nov 23;343 (21):1520-8, 2 p following 1528
SSID ssj0017853
Score 2.1678162
Snippet Mycobacterium tuberculosis (TB) is one of the world's most devastating public health threats. Our goal is to evaluate whether the use of non-steroidal...
Background Mycobacterium tuberculosis (TB) is one of the world’s most devastating public health threats. Our goal is to evaluate whether the use of...
Abstract Background Mycobacterium tuberculosis (TB) is one of the world’s most devastating public health threats. Our goal is to evaluate whether the use of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 82
SubjectTerms Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Case-Control Studies
Coxibs
Cyclooxygenase 2 Inhibitors - therapeutic use
Cyclooxygenase-2
Databases, Factual
Female
Health insurance
Health risk assessment
Humans
Inflammation
Logistic Models
Longitudinal Studies
Male
Middle Aged
Multivariate Analysis
National Health Programs
Nonsteroidal anti-inflammatory drugs
NSAIDs
Population studies
Population-based studies
Public health
Pulmonology
Risk Factors
Studies
Taiwan - epidemiology
Time Factors
Tuberculosis
Tuberculosis - epidemiology
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojy3FGQkTkhW87BjmxsgqgqpHBCVerP8hBUlqTabn8D_7ozjjboIwYVLDvZYcTyfPWOP8w0hr5tW6No3ATY5wjGeuoq5aBtWh9hKkeCZaRfPP3dnF_zTpbi8leoL74TN9MDzwJ24gJnv6lR1znFnpfNJ1cKBY2E5TI68-oLN222mSvxAghUqMcxadSdjjfE0hisygpS1e1Yok_X_ycP8_aLkLctz-oDcLy4jfTd39ZDcif1Dcve8BMUfkV9f1uMPOiSKx-b43y21eRGj28nFjZ-uhnE90hKJASFauFRHmm-Zx0DxMJb2Q8-QNWFYB3gbDPiaAfoAMD9zIJ6GzfRtfEstvV5yfjG0gYFmitrH5OL049cPZ6xkV2Ce63bLpLCaW8WD7qyQyTZVbJP0ETkEeRWTdWDZXdAKihsfOq0sUu2APxmiaqvUPiEH0LP4jNCgtPS20ipVnstKOSeVtSLx0HhQebsi1W60jS_U45gB48rkLYjqzKwgAwoyqCADTd4sTa5n3o2_Cb9HFS6CSJmdCwBIpgDJ_AtIK3K8A4Ap83g04C4JTDGg1Yq8WqphBmJYxfZxmEBGIcENuHYg83TGy9ITNP6N5nxF5B6S9rq6X9Ovv2eWb8ExW5g8-h_f9pzcazL4BeD_mBxsN1N8Ac7U1r3M8-YGqjoe6w
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gggien6tnhLBJyFcP5Im9UVUPA7hfBAP9i3k81zubNft9k_w_3YmzVZX5F760E5p6PwyM5lJfkPI66oWbekqD4scYRmPTcFsMBUrfailiHBNtItnX5rTc_55KZY54TbkbZU7m5gMte8d5siPwXEJJHtv1bv1T4Zdo7C6mlto3CS3kLoMt3TJ5bzgwsbzda5klqo5HkqsqjG0ywhVVu_5okTZ_78489_tkn_5n5P75F4OHOn7SdMPyI3QHZLbZ7k0fkjuTgk4Op0rekh-fV0Nl7SPFJPpeBqXmmTa6Ha0YePGq35YDTTXZ0CIZobVgaa958FTTNHSru8Ycin0Kw9fBzWsGGASYPQjleep34wXw1tq6HruBMbQM3qaiGsfkfOTT98-nrLcc4E53tZbJoVpuVHct40RMpqqCHWULiCzIC9CNBb8vfWtgtuV802rDBLwQJTpg6qLWD8mBzCy8JRQr1rpTNGqWDguC2WtVMaIyH3lAAj1ghS7v69dJiTHvhhXOi1MVKMnhWlQmEaFaXjlzfzKemLjuE74A6p0FkQi7XSj31zoPC-19dhYsYxFYy23RloXVSksxK2Gg-2tFuRoBwidZ_eg_2BxQV7Nj2FeYrHFdKEfQUYh7Q0EfCDzZMLPPBIMCaqW8wWRe8jaG-r-k271PXF_C449xOSz64f1nNypEswFIP2IHGw3Y3gBwdPWvkwz5DeqFBuB
  priority: 102
  providerName: ProQuest
Title Risk of incident active tuberculosis disease in patients treated with non-steroidal anti-inflammatory drugs: a population-based study
URI https://www.ncbi.nlm.nih.gov/pubmed/28472944
https://www.proquest.com/docview/1905074798
https://www.proquest.com/docview/1896040648
https://pubmed.ncbi.nlm.nih.gov/PMC5418697
https://doaj.org/article/bd00581f06bb4ba7bcf815b650a43762
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA_3AeKL-O3quUTwSYj2I2lSQcSVOw5hD1lcWHwpSZPcLa7t2W5B_wD_b2ey3erKIvjSh3bShsxvMpNM-htCniepyOMysbDIEYZxn0XMOJ2w2LpUCg_XQLs4vcjO5_zDQiwOyLa8VT-A7d6lHdaTmjerl9-__XgLBv8mGLzKXrUxZssYzrcIQZYekmNwTBLtdMp_JxWkCqSUMczHLOFZ1ic5975ix00FNv99IejfJyn_cE1nt8mtPqak7zYguEMOXHWX3Jj2WfN75Ods2X6htae4r44_5lIdZjm67oxrym5Vt8uW9qkaEKI92WpLwzF0Zynu1tKqrhjSKtRLC18DjSwZDBgg6mvI1FPbdJfta6rp9VAUjKGTtDRw2N4n87PTT-_PWV9-gZU8T9dMCp1zrbjNMy2k10nkUi9LhySDPHJeG3D9xuYKbielzXKlkYsHAk7rVBr59AE5gp65R4RalctSR7nyUcllpIyRSmvhuU1KwEQ6ItF2tIuy5ybHEhmrIqxRVFZsFFSAggpUUAFNXgxNrjfEHP8SnqAKB0Hk1A436uay6E20MBZrLMY-yozhRktTehULAyGs5jANJyNysgVAscVpAfGUwBoEuRqRZ8NjMFHMu-jK1R3IKGTAgdgPZB5u8DL0BKODJOd8ROQOkna6uvukWl4FGnDBsZyYfPw_A_GE3EwCyAXg_IQcrZvOPYWoam3G5FAu5JgcT04vPs7GYW9iHOwHrrPJ51_SaiNm
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwELXKVgIkhKDcFgoYCV6QrOZiJw4SQhRabWl3hapW6lvwtV21bJbNrhAfwO_wjcw42cAi1Le-5MGZJFbmeGbssc8Q8jJJRRGbxMIkR2jGfRYx7VTCYuvSXHi4BtrF4SgbHPNPJ-JkjfxanoXBbZVLmxgMta0MrpFvgeMSSPZeyHfTbwyrRmF2dVlCo4HFvvvxHaZs9du9j6DfV0myu3P0YcDaqgLM8CKds1yogivJbZEpkXuVRC71uXHInccj55UGj6ZtIaE5MTYrpEKKGYijrJNp5FN47zWyzlOYyvTI-vbO6PNhl7fIwfu1udNYZlt1jHk8hp4ABwdLV7xfKBLwv8j23w2af3m83Tvkdhuq0vcNtu6SNTfZINeHbTJ-g9xqlvxoc5LpHvl5OK7PaeUpLt_j-V-qgjGl84V2M7O4qOpxTduMEAjRltO1pmG3u7MUF4XppJowZG-oxha-DoofMxgFANyvYUMAtbPFaf2GKjrtao8x9MWWBqrc--T4SvTxgPSgZ-4RoVYWuVFRIX1keB5JrXOplPDcJgagl_ZJtPz7pWkp0LESx0UZpkIyKxuFlaCwEhVWwiOvu0emDf_HZcLbqNJOEKm7Q0M1Oy1bS1Bqi6UcYx9lWnOtcm28jIWGSFlxsPZJn2wuAVG29qQu_6C_T150t8ESYHpHTVy1ABmJRDsQYoLMwwY_XU8wCEkKzvskX0HWSldX70zGZ4FtXHCsWpY_vrxbz8mNwdHwoDzYG-0_ITeTAHkBqN8kvfls4Z5C6DbXz9rxQsmXqx6ivwFgGFmy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+incident+active+tuberculosis+disease+in+patients+treated+with+non-steroidal+anti-inflammatory+drugs%3A+a+population-based+study&rft.jtitle=BMC+pulmonary+medicine&rft.au=Wu%2C+Chun-Wei&rft.au=Wu%2C+Jiunn-Yih&rft.au=Lee%2C+Meng-Tse+Gabriel&rft.au=Lai%2C+Chih-Cheng&rft.date=2017-05-04&rft.issn=1471-2466&rft.eissn=1471-2466&rft.volume=17&rft.issue=1&rft_id=info:doi/10.1186%2Fs12890-017-0425-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12890_017_0425_3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2466&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2466&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2466&client=summon